Investigational treatment combining TG1050, an HBV-specific immunotherapeutic, with direct acting antivirals or immunomodulators, improves sustained antiviral effects and immune responses in HBV-persistent mice

Roland Kratzer, et al.
AASLD, The Liver Meeting 2018, November 2018 – Abstract available on the AASLD website
Download the poster here
Poster Presentation

Collaboration between Transgene – Laboratoire de Recherches Biochirurgicales, Université Paris Descartes, Hôpital Européen Georges Pompidou, Paris, France – Université Paris Diderot, Sorbonne Paris Cité, Paris, France – Hôpital Saint-Louis, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France – Alnylam Pharmaceuticals, Cambridge, USA – The State Key Laboratory of Anti-Infection Drug Development, HEC Pharma Group, Dong Guan, China